173 related articles for article (PubMed ID: 24875819)
1. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy.
Wu JP; Huang WB; Zhou H; Xu LW; Zhao JH; Zhu JG; Su JH; Sun HB
Asian J Androl; 2014; 16(5):710-4. PubMed ID: 24875819
[TBL] [Abstract][Full Text] [Related]
2. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma.
Tomas D; Spajić B; Milosević M; Demirović A; Marusić Z; Kruslin B
Scand J Urol Nephrol; 2010 Nov; 44(5):284-90. PubMed ID: 20459359
[TBL] [Abstract][Full Text] [Related]
3. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
4. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR
Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
6. [Phenotypic differences of stroma cells in benign and malignant human prostate tissues].
Zhou H; Sun HB; Huang WB; Xu Z; Su JH; Zhu JG; Jia RP; Liu J
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):516-9. PubMed ID: 22490152
[TBL] [Abstract][Full Text] [Related]
7. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
8. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
[TBL] [Abstract][Full Text] [Related]
9. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.
Yanagisawa N; Li R; Rowley D; Liu H; Kadmon D; Miles BJ; Wheeler TM; Ayala GE
Hum Pathol; 2007 Nov; 38(11):1611-20. PubMed ID: 17868773
[TBL] [Abstract][Full Text] [Related]
10. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma.
Tomas D; Kruslin B
Prostate; 2004 Dec; 61(4):324-31. PubMed ID: 15389817
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.
Blom S; Erickson A; Östman A; Rannikko A; Mirtti T; Kallioniemi O; Pellinen T
Prostate; 2019 Sep; 79(13):1505-1513. PubMed ID: 31269283
[TBL] [Abstract][Full Text] [Related]
12. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.
Tuxhorn JA; Ayala GE; Smith MJ; Smith VC; Dang TD; Rowley DR
Clin Cancer Res; 2002 Sep; 8(9):2912-23. PubMed ID: 12231536
[TBL] [Abstract][Full Text] [Related]
13. Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma.
Tomas D; Ulamec M; Hudolin T; Bulimbasić S; Belicza M; Kruslin B
Prostate Cancer Prostatic Dis; 2006; 9(4):414-9. PubMed ID: 16652121
[TBL] [Abstract][Full Text] [Related]
14. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival.
Hägglöf C; Hammarsten P; Josefsson A; Stattin P; Paulsson J; Bergh A; Ostman A
PLoS One; 2010 May; 5(5):e10747. PubMed ID: 20505768
[TBL] [Abstract][Full Text] [Related]
15. Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells.
Silva MM; Matheus WE; Garcia PV; Stopiglia RM; Billis A; Ferreira U; Fávaro WJ
Int Braz J Urol; 2015; 41(5):849-58. PubMed ID: 26689510
[TBL] [Abstract][Full Text] [Related]
16. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
17. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
[TBL] [Abstract][Full Text] [Related]
18. Stromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer.
Yang Z; Peng YC; Gopalan A; Gao D; Chen Y; Joyner AL
Dis Model Mech; 2017 Jan; 10(1):39-52. PubMed ID: 27935821
[TBL] [Abstract][Full Text] [Related]
19. Adenocarcinoma on needle prostatic biopsies: does reactive stroma predicts biochemical recurrence in patients following radical prostatectomy?
Billis A; Meirelles L; Freitas LL; Polidoro AS; Fernandes HA; Padilha MM; Magna LA; Reis LO; Ferreira U
Int Braz J Urol; 2013; 39(3):320-7. PubMed ID: 23849565
[TBL] [Abstract][Full Text] [Related]
20. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.
Singer E; Linehan J; Babilonia G; Imam SA; Smith D; Loera S; Wilson T; Smith S
PLoS One; 2013; 8(6):e60562. PubMed ID: 23762225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
